Genzyme, International Chemical Investors Group deal

International Chemical will acquire Genzyme's pharmaceutical intermediates business, excluding the drug delivery technologies portion, for an undisclosed amount. The unit develops and manufactures chemically synthesized pharmaceutical materials and technologies and focuses on lipids, peptides, carbohydrates, oligonucleotides and custom small molecules. Genzyme said International Chemical agreed to offer employment to the unit's 120 employees and plans to maintain operations at its primary Liestal, Switzerland, location. The unit will be renamed Corden Pharma Switzerland LLC and will operate as part of International Chemical's Corden Pharma business. The deal is expected to close this quarter. Young & Partners advised Genzyme. ...